---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-061346"
form_type: "8-K"
ticker: "ORGO"
cik: "0001661181"
company_name: "Organogenesis Holdings Inc."
filed_at: "2022-03-01T23:59:59+00:00"
generated_at: "2026-06-27T03:04:37.873213+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Organogenesis Q4 revenue $128.6M (+20% YoY), FY22 guidance $485M-$515M

## Summary
- Q4 net revenue $128.6M (up 20% YoY); Advanced Wound Care $121.4M (+30%), Surgical & Sports Medicine $7.2M (-45%).
- Q4 GAAP net income $51.7M ($0.39 diluted EPS) vs $18.3M ($0.15) a year ago; adjusted EBITDA $26.3M.
- FY2021 net revenue $468.1M (+38% YoY); net income $94.9M ($0.71 diluted EPS); adjusted EBITDA $89.1M.
- FY2022 guidance: net revenue $485M-$515M (+4% to +10% YoY); net income $56.5M-$71.5M; adjusted EBITDA $79.9M-$95.3M.
- Cash and equivalents $114.5M; total debt $73.6M as of Dec 31, 2021.

## SEC filing metadata
- accession: 0001193125-22-061346
- form_type: 8-K
- ticker: ORGO
- cik: 0001661181
- company_name: Organogenesis Holdings Inc.
- filed_at: 2022-03-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661181/000119312522061346/0001193125-22-061346-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661181/000119312522061346/d325515d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-061346
- JSON: https://secwatch.observer/filing/0001193125-22-061346.json
- Plain text: https://secwatch.observer/filing/0001193125-22-061346.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.